Last update 28 Jan 2026

CN-202

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
CN 202, CN-202
Target
PDL1 x TGF-β
Action
inhibitors
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Locally Advanced Malignant Solid NeoplasmMetastatic Solid Tumor
Inactive Indication
Hematologic Neoplasms
Originator Organization
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
Active Organization
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CN-202
NCT05028478
/ Not yet recruitingPhase 1/2
An Open-Label, Multi-center, Phase I/II Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
100 Clinical Results associated with CN-202
Login to view more data
100 Translational Medicine associated with CN-202
Login to view more data
100 Patents (Medical) associated with CN-202
Login to view more data
100 Deals associated with CN-202
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Malignant Solid NeoplasmPhase 2-
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
22 Oct 2021
Metastatic Solid TumorPhase 2-
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
22 Oct 2021
Hematologic NeoplasmsIND Approval
China
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
04 Nov 2021
Solid tumorIND Approval
China
Curon Biopharmaceutical Ltd.Curon Biopharmaceutical Ltd.
04 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free